Extended Release Tacrolimus (LCP-TAC) Prolongs Calcineurin Activity Inhibition During Drug Doses Intervals

    loading  Checking for direct PDF access through Ovid

Abstract

Introduction

Tacrolimus (TAC) is the cornerstone calcineurin inhibitors most commonly used in renal transplantation. New extended release formulation of tacrolimus (LCPT-ER) (Envarsus®) offers better bioavailability and less fluctuation between maximum concentration (Cmax) and trough and with a lower peak level compared to immediate-release (TAC-IR) formulation (Prograf® or Adoport®). The more stable and less fluctuating TAC exposure of LCPT-ER may result in an optimized pharmacodynamic (PD) profile with a more sustained inhibition of calcineurin activity (CNA) during dose intervals.

Introduction

The goal of this study is to compare the CNA area under the curve (AUC) between LCPT-ER and TAC-IR formulation in kidney stable transplant patients and their correlation with their corresponding TAC exposures.

Methodology

An open-label, prospective, non-randomized study investigator-driven was conducted. Ten patients receiving TAC-IR in steady state were subsequently switched to LCPT-ER (dose conversion rate 1:0.7). Before and after conversion, pharmacokinetic (PK) and PD intensive analysis were conducted along 24 hours (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 15, 20 and 24h). A validated method by UPLC-MS based on peptide dephosphorilation was used to measure CNA in peripheral blood mononuclear cells. TAC levels in whole blood were measured also by UPLC-MS. Concentration of TAC in blood is expressed in μg/L. CN activity is expressed in pmol of dephosporilated peptide/time x protein (pmol/m·mg). To evaluate the duration of CNA inhibition between drug doses intervals, the CNA Imax was subtracted to CNA at each time point (AUC PD Imax).

Results

PK results showed that LCPT-ER presented lower Cmax and higher dose normalized AUC PK0-24 than TAC-IR statistically significant. These results are illustrated in Table 1.

Results

AUC PDIo displayed similar values between LCPT-ER and TAC-IR, but as PK, LCPT-ER achieved significative higher inhibition when they were normalized by doses. A lower AUC PDImax value of LCPT-ER was obtained, indicating more maintained inhibition along the curve. PD parameters are shown in table 2 and an illustration of CN activity during 24 hours with both formulations is presented in Figure 1.

Conclusions

Our results expressed that with lower doses of LCPT-ER similar TAC exposure and CNA inhibition were obtained. Furthermore, LCPT-ER showed a CNA inhibition-time curve strongly more maintained along drug doses intervals compared with TAC-IR formulation. Only with LCPT-ER formulation, CNA levels did not reach the pre-dose in any point of the PD study.

Conclusions

An unrestricted grant from Chiesi.

Related Topics

    loading  Loading Related Articles